iRadimed Corporation (NASDAQ:IRMD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of iRadimed Corporation (NASDAQ:IRMD) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $87.3333.

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Thursday. Roth Capital set a $90.00 price objective on iRadimed in a report on Friday, October 31st. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Lake Street Capital reissued a “buy” rating and set a $100.00 target price on shares of iRadimed in a report on Monday, November 3rd. Finally, Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th.

Insider Activity

In other news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $90.36, for a total transaction of $451,800.00. Following the completion of the sale, the chief executive officer owned 2,307,500 shares of the company’s stock, valued at $208,505,700. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 50,000 shares of company stock worth $3,840,650 over the last ninety days. 36.80% of the stock is owned by corporate insiders.

Institutional Trading of iRadimed

Several large investors have recently bought and sold shares of IRMD. Nuveen LLC purchased a new stake in shares of iRadimed in the first quarter valued at approximately $1,418,000. Vanguard Group Inc. increased its stake in shares of iRadimed by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 554,451 shares of the medical equipment provider’s stock worth $29,098,000 after acquiring an additional 17,640 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of iRadimed by 13.8% during the 1st quarter. American Century Companies Inc. now owns 18,284 shares of the medical equipment provider’s stock worth $960,000 after acquiring an additional 2,213 shares during the period. Voya Investment Management LLC boosted its position in shares of iRadimed by 38.2% during the 1st quarter. Voya Investment Management LLC now owns 11,711 shares of the medical equipment provider’s stock valued at $615,000 after acquiring an additional 3,239 shares during the last quarter. Finally, Johnson Investment Counsel Inc. purchased a new stake in shares of iRadimed in the second quarter valued at about $1,534,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Price Performance

iRadimed stock opened at $94.57 on Monday. The stock has a market capitalization of $1.20 billion, a PE ratio of 57.32 and a beta of 1.06. The business has a 50 day simple moving average of $81.57 and a 200-day simple moving average of $69.92. iRadimed has a 12 month low of $47.48 and a 12 month high of $94.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The firm had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, equities research analysts anticipate that iRadimed will post 1.66 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, November 25th. Shareholders of record on Friday, November 14th were paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. iRadimed’s payout ratio is 41.21%.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.